Selective serotonin reuptake inhibitor use during pregnancy and possible neonatal complications.
This paper reviews the risks and benefits of using selective serotonin reuptake inhibitors (SSRIs) in pregnant women. The effects of SSRI use on pregnant women and fetuses are discussed, and the need for SSRI treatment is explained. Persistent pulmonary hypertension of the newborn, teratogenic risks of SSRI treatment during pregnancy, neonatal adaptations, and long-term outcomes for children whose mothers used SSRIs during pregnancy are specifically considered. Due to conflicting results from current studies, there are no clear guidelines for SSRI treatment in pregnancy. Patients and doctors must discuss together the risks and benefits of SSRI use during pregnancy and decide on a course of treatment. Potential risks must be balanced against the effects of untreated maternal depression.
Cantor Sackett
Jillan
J
Department of Psychiatry, Thomas Jefferson University Hospital, 833 Chestnut Street, Suite 210, Philadelphia, PA 19107, USA. jillan.cantor@jeffersonhospital.org
Weller
Ronald A
RA
Weller
Elizabeth B
EB
D000014:Abnormalities, Drug-Induced / Q000209:etiology; D003866:Depressive Disorder / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D012307:Risk Factors; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*
D017367:Selective Serotonin Reuptake Inhibitors